Cannabix Technologies Files Breath Sample Capture Patent and Detects Delta- 8 THC in Early Testing
August 04 2023 - 8:52AM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2023/8/3/Aspose.Words.6c5e732f-2224-492b-a18b-d262c4a9c481.001.png)
Cannabix Technologies Files
Breath Sample Capture Patent and Detects Delta- 8 THC in Early
Testing
Vancouver, British Columbia, Canada -- August 4, 2023 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (the "Company or Cannabix") developer of marijuana
and alcohol breath testing devices reports that it has filed an
International Patent Application ("PCT") titled, "Apparatus and
Methods for Capturing Non-Volatile and Semi-Volatile Substances
from Breath". This PCT application covers new innovations and
intellectual property related the development to the detection of
volatile organic compounds (VOCs) and Semi-Volatile Substances
(like delta-9 THC) using the handheld Cannabix Breath Collection
Unit ("BCU"). The BCU allows for the efficient collection,
adsorption and desorption of analytes of low volatility from human
breath.
Highlights and Updates:
- The Company has
filed a new patent for its BCU related technology allowing for
effective breath sample collection from humans for typically very
difficult to detect non-volatile compounds in breath (like delta-9
THC).
- Cannabix's Mass
Spectrometer Breath Sampler ("MSBS") technology along with BCU have
been providing consistent results in the detection of delta-9 THC
in breath from smoking and THC infused edibles consumption. The
Company reports that early testing with Delta- 8 THC in standards,
in the low 10-100 picogram range, have been detected using the MSBS
technology. Delta-8 THC is present in small amounts in hemp and has
psychoactive and intoxicating effects, similar though less potent
compared to delta-9 THC. Since it is extracted from legal
forms of cannabis and concentrated, it has been of increasing
concern for law enforcement and state governments. The Company is
planning testing with metabolized delta-8 THC.
- Cannabix is
advancing discussions with industry leading forensic laboratory
organizations on how to best integrate its novel MSBS hardware into
current forensic testing and analysis methods.
- California to
usher in a new employment statute for cannabis testing that will
position breath testing for cannabis as an important alternative to
legacy methods.
The new PCT
covers various novel methods for efficient collection of analytes
of low volatility from human breath developed by the Company.
This includes liquid secondary adsorption, the concept behind the
MSBS, which has repeatedly demonstrated efficient capture and
release of THC. This novel method uses the breath aerosol as a
carrier of solid and viscous liquid particle analytes as well as a
secondary adsorbent to prevent sample loss from droplet surface
contact and deposition. This is a unique capability in that current
methods focus solely on volatile analytes in breath, while the
non-volatile components provide much more information about the
subject. Cannabix has been continuously improving collection
efficiency of the BCU, and sample transfer efficiency of the MSBS
such that the results are comparable or better relative to
conventional Liquid chromatography–mass spectrometry (LC-MS)
forensic methods, which are time-consuming and expensive.
Breath samples
collected portably with the BCU have detected and confirmed delta-9
THC in breath out to 4 hours after smoking even after being stored
and analyzed up to two days after sample collection, demonstrating
the robustness and utility of the method. The Company is advancing
discussions with industry leading forensic laboratory organizations
on how to best integrate its BCU and MSBS hardware into current
forensic testing and analysis methods. Cannabix's marijuana breath
testing technologies are meeting the growing demand for new
non-invasive, fairer, and more accurate delta-9 THC testing.
Significant changes
in California's employment laws have been adopted by its state
legislature (known as "Assembly Bill 2188" or "AB 2188") whereby
employers in California will be prohibited from making employment
decisions based upon the presence of non-psychoactive cannabis metabolites in
drug screening – these are molecules that stay in a cannabis user's
system for days, weeks, or even months after use. Furthermore,
employers will need to ensure that commencing January 1, 2024, they
do not make any adverse employment decisions based upon an
applicant's or employee's off-duty cannabis use (1). Cannabix's
MSBS technology has been specifically built to detect recent cannabis use – detecting Delta-9
THC, the psychoactive component of marijuana that causes impairment
– using breath samples, within 1-4 hours after consumption.
Rav Mlait, CEO, commented, "We have been steadily growing and
strengthening our intellectual property portfolio in the arena of
breath testing -- this is testament to the ability of Cannabix
engineers to innovate. Our BCU and MSBS hardware continue to show
very good sensitivity due to the ability to effectively collect and
desorb breath samples containing non-volatiles like delta-9
THC."
(1)
https://www.perkinscoie.com/en/news-insights/california-to-protect-employee-off-duty-cannabis-use-effective-2024.html
About Cannabix
Technologies Inc.
Cannabix
Technologies Inc. is a developer of marijuana and alcohol
breathalyzer technologies for law enforcement, workplaces and
laboratories. Cannabix is working to develop delta-9 THC and
alcohol screening devices. Delta-9 THC is the psychoactive
component of marijuana that causes impairment. Breath testing for
delta-9 THC would allow employers and law enforcement
to identify recent marijuana use that better aligns with
impairment. Cannabix is the developer of contactless breath alcohol detection
devices for employers and other settings.
We seek Safe
Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix
Technologies Inc.
For further
information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that its development of
breathalyzer technologies will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. The is no
assurance that the Company will enter into any partnerships to
advance any of its corporate initiatives or technologies. There is
no assurance that any "patent pending" or "provisional patents"
technologies licensed by the Company or owned by the Company will
receive patent status by regulatory authorities. The Company
is not currently selling commercial breathalyzers. Actual results
and future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.
501-3292 Production Way, Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Aug 2023 to Aug 2024